Research ExplorerPublicationsTormentil for active ulcerative colitis: an open-label, dose...

Tormentil for active ulcerative colitis: an open-label, dose-escalating study

Standard

Tormentil for active ulcerative colitis: an open-label, dose-escalating study. / Huber, Roman; Ditfurth, Amelie V; Amann, Frank; Güthlin, Corina; Rostock, Matthias; Trittler, Rainer; Kümmerer, Klaus; Merfort, Irmgard.

In: Journal of clinical gastroenterology, Vol. 41, No. 9, 10.2007, p. 834-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Huber, R, Ditfurth, AV, Amann, F, Güthlin, C, Rostock, M, Trittler, R, Kümmerer, K & Merfort, I 2007, 'Tormentil for active ulcerative colitis: an open-label, dose-escalating study', Journal of clinical gastroenterology, vol. 41, no. 9, pp. 834-8. https://doi.org/10.1097/MCG.0b013e31804b2173

APA

Huber, R., Ditfurth, A. V., Amann, F., Güthlin, C., Rostock, M., Trittler, R., Kümmerer, K., & Merfort, I. (2007). Tormentil for active ulcerative colitis: an open-label, dose-escalating study. Journal of clinical gastroenterology, 41(9), 834-8. https://doi.org/10.1097/MCG.0b013e31804b2173

Vancouver

Huber R, Ditfurth AV, Amann F, Güthlin C, Rostock M, Trittler R et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. Journal of clinical gastroenterology. 2007 Oct;41(9):834-8. https://doi.org/10.1097/MCG.0b013e31804b2173

Bibtex

@article{98dd65c6d7b34682a0281bfa2e192a5f,
title = "Tormentil for active ulcerative colitis: an open-label, dose-escalating study",
abstract = "BACKGROUND: Tormentil extracts (TE) have antioxidative properties and are used as a complementary therapy for chronic inflammatory bowel disease. In individual patients with ulcerative colitis (UC) positive effects have been observed.GOALS: To assess the safety, pharmacology, and clinical effects of different doses of TE in patients with active UC.STUDY: Sixteen patients with active UC [clinical activity index (CAI) >/=5] received TE in escalating doses of 1200, 1800, 2400 and 3000 mg/d for 3 weeks each. Each treatment phase was followed by a 4-week washout phase. The outcome parameters were side effects, CAI, C-reactive protein, and tannin levels in patient sera.RESULTS: Mild upper abdominal discomfort was experienced by 6 patients (38%), but did not require discontinuation of the medication. During therapy with 2400 mg TE per day, median CAI and C-reactive protein improved from 8 (6 to 10.75) and 8 (3 to 17.75) mg/L at baseline to 4.5 (1.75 to 6) and 3 (3 to 6) mg/L, respectively. During therapy, the CAI decreased in all patients, whereas it increased during the washout phase. Neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry (LC-MS) in patient sera.CONCLUSIONS: TE appeared safe up to 3000 mg/d. Tannins from TE are not systemically absorbed. The efficacy in patients with UC should be further evaluated.",
keywords = "Adolescent, Adult, Aged, C-Reactive Protein/drug effects, Chromatography, Liquid, Colitis, Ulcerative/drug therapy, Dose-Response Relationship, Drug, Female, Humans, Male, Mass Spectrometry, Middle Aged, Phytotherapy, Plant Extracts/administration & dosage, Plants, Medicinal, Potentilla/chemistry, Rhizome, Severity of Illness Index, Tannins/blood",
author = "Roman Huber and Ditfurth, {Amelie V} and Frank Amann and Corina G{\"u}thlin and Matthias Rostock and Rainer Trittler and Klaus K{\"u}mmerer and Irmgard Merfort",
year = "2007",
month = oct,
doi = "10.1097/MCG.0b013e31804b2173",
language = "English",
volume = "41",
pages = "834--8",
journal = "J CLIN GASTROENTEROL",
issn = "0192-0790",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

RIS

TY - JOUR

T1 - Tormentil for active ulcerative colitis: an open-label, dose-escalating study

AU - Huber, Roman

AU - Ditfurth, Amelie V

AU - Amann, Frank

AU - Güthlin, Corina

AU - Rostock, Matthias

AU - Trittler, Rainer

AU - Kümmerer, Klaus

AU - Merfort, Irmgard

PY - 2007/10

Y1 - 2007/10

N2 - BACKGROUND: Tormentil extracts (TE) have antioxidative properties and are used as a complementary therapy for chronic inflammatory bowel disease. In individual patients with ulcerative colitis (UC) positive effects have been observed.GOALS: To assess the safety, pharmacology, and clinical effects of different doses of TE in patients with active UC.STUDY: Sixteen patients with active UC [clinical activity index (CAI) >/=5] received TE in escalating doses of 1200, 1800, 2400 and 3000 mg/d for 3 weeks each. Each treatment phase was followed by a 4-week washout phase. The outcome parameters were side effects, CAI, C-reactive protein, and tannin levels in patient sera.RESULTS: Mild upper abdominal discomfort was experienced by 6 patients (38%), but did not require discontinuation of the medication. During therapy with 2400 mg TE per day, median CAI and C-reactive protein improved from 8 (6 to 10.75) and 8 (3 to 17.75) mg/L at baseline to 4.5 (1.75 to 6) and 3 (3 to 6) mg/L, respectively. During therapy, the CAI decreased in all patients, whereas it increased during the washout phase. Neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry (LC-MS) in patient sera.CONCLUSIONS: TE appeared safe up to 3000 mg/d. Tannins from TE are not systemically absorbed. The efficacy in patients with UC should be further evaluated.

AB - BACKGROUND: Tormentil extracts (TE) have antioxidative properties and are used as a complementary therapy for chronic inflammatory bowel disease. In individual patients with ulcerative colitis (UC) positive effects have been observed.GOALS: To assess the safety, pharmacology, and clinical effects of different doses of TE in patients with active UC.STUDY: Sixteen patients with active UC [clinical activity index (CAI) >/=5] received TE in escalating doses of 1200, 1800, 2400 and 3000 mg/d for 3 weeks each. Each treatment phase was followed by a 4-week washout phase. The outcome parameters were side effects, CAI, C-reactive protein, and tannin levels in patient sera.RESULTS: Mild upper abdominal discomfort was experienced by 6 patients (38%), but did not require discontinuation of the medication. During therapy with 2400 mg TE per day, median CAI and C-reactive protein improved from 8 (6 to 10.75) and 8 (3 to 17.75) mg/L at baseline to 4.5 (1.75 to 6) and 3 (3 to 6) mg/L, respectively. During therapy, the CAI decreased in all patients, whereas it increased during the washout phase. Neither undegraded nor metabolized tannins could be detected by liquid-mass spectrometry (LC-MS) in patient sera.CONCLUSIONS: TE appeared safe up to 3000 mg/d. Tannins from TE are not systemically absorbed. The efficacy in patients with UC should be further evaluated.

KW - Adolescent

KW - Adult

KW - Aged

KW - C-Reactive Protein/drug effects

KW - Chromatography, Liquid

KW - Colitis, Ulcerative/drug therapy

KW - Dose-Response Relationship, Drug

KW - Female

KW - Humans

KW - Male

KW - Mass Spectrometry

KW - Middle Aged

KW - Phytotherapy

KW - Plant Extracts/administration & dosage

KW - Plants, Medicinal

KW - Potentilla/chemistry

KW - Rhizome

KW - Severity of Illness Index

KW - Tannins/blood

U2 - 10.1097/MCG.0b013e31804b2173

DO - 10.1097/MCG.0b013e31804b2173

M3 - SCORING: Journal article

C2 - 17881930

VL - 41

SP - 834

EP - 838

JO - J CLIN GASTROENTEROL

JF - J CLIN GASTROENTEROL

SN - 0192-0790

IS - 9

ER -